In-vitro differential metabolism and activity of 5-fluorouracil between short-term, high-dose and long-term, low-dose treatments in human squamous carcinoma cells

Anti-Cancer Drugs

Volumn 17, Issue 4, 2006, Pages 439-443

  Qin, Baoli ^a   Tanaka, Risa ^a   Ariyama, Hiroshi ^a   Shibata, Yoshihiro ^a   Arita, Shuji ^a   Kusaba, Hitoshi ^a   Baba, Eishi ^a   Harada, Mine ^a   Nakano, Shuji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

5 fluorodeoxyuridine monophosphate; 5 fluorouracil; Bolus; Continuous; Fluorinated RNA; Thymidylate synthase activity

Indexed keywords

FLOXURIDINE PHOSPHATE; FLUOROURACIL; LIGAND; RNA; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING ASSAY; BINDING COMPETITION; BINDING SITE; CAPILLARY GAS CHROMATOGRAPHY; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG INFUSION; DRUG MEGADOSE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORINATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIGAND BINDING; LONG TERM EXPOSURE; LOW DRUG DOSE; MASS SPECTROMETRY; PRIORITY JOURNAL; RADIOASSAY; RNA ANALYSIS; SHORT COURSE THERAPY; SQUAMOUS CELL CARCINOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; RNA; THYMIDYLATE SYNTHASE; TONGUE NEOPLASMS;

EID: 33748172884     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000203380.22361.6c     Document Type: Article

References (19)

1. Grem LG. Fluorinated pyrimidines. In: Chabner BA, Collin JM (editors): Cancer chemotherapy: principles and practice. Philadelphia: Lippincott; 1990. pp. 180-224.
2. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-308.
3. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7:425-432.
4. Rougier P, Paillot B, LaPlanche A, Morvan F, Seitz JF, Rekacewicz C, et al. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur J Cancer 1997; 33:1789-1793.
5. Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52:1855-1864.
6. Tsujinaka T, Kido Y, Shiozaki H, Iijima S, Homma T, Sakaue M, Mori T. Schedule-dependent inhibition of thymidylate synthase by 5-fluorouracil in gastric cancer. Cancer 1992; 70:2761-2765.
7. Nakano S, Nakayama M, Ichinose I, Mitsugi K, Nagafuchi S, Niho Y. Characterization of a newly established, TA-4-producing squamous carcinoma cell line derived from metastatic tongue carcinoma. Int J Cancer 1989; 44:301-306.
8. Jol C, Kuppen P, Leeflang PA, van Oosterom AT, Tjaden UR, de Bruijn EA. In-vitro pharmacology of mitomycin C in human ovarian cancer. In: Taguchi T, Andrysek O (editors): New trends in cancer chemotherapy with mitomycin C. Amsterdam: Excerpta Medica; 1987. pp. 181-191.
9. Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L, et al. Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 1984; 44:4144-4150.
10. Masuike T, Kikuchi K, Saitoh A, Hashimoto T, Takemoto Y. Assay of 5-fluorouracil uptaken into the tissue RNA using gas chromatography-mass spectrometry. Antibiot Chemother 1995; 11:162.
11. Skeel RT. Handbook of cancer chemotherapy. Philadelphia: Lippincott Williams & Wilkins; 2003. pp. 8-9.
12. Parker WB, Cheng Y. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990; 48:381-395.
13. Cooney ADA, Jayaram HN, Carrico CK, Glazer RI, Macdonald J, Schein PS. Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil. Cancer Res 1980; 40:1431-1437.
14. Fukushima M, Ikenaka K, Shirasaka T, Fujii S. Metabolism of 5-fluorouracil in sensitive and resistant tumor cells. Gann 1979; 70:47-53.
15. Uchida J, Umeno Y, Takeda S. Significance of measuring 5-fluorouracil incorporated into RNA of tumor tissue as a parameter for the antitumor activity of 5-fluorouracil and its analogs. Gan To Kagaku Ryoh 1992; 19:677-683.
16. AbdAlla EE, Blair GE, Jones RA, Sue-Ling HM, Johnston D. Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. J Natl Cancer Inst 1995; 87:489-496.
17. Ghoshal K, Jacob ST. Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res 1994; 54:632-636.
18. Evans RM, Laskin JD, Hakala MT. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res 1980; 40:4113-4122.
19. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH. In-vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982; 42:450-456.